ATAGI statement on recommendations on a winter booster dose of COVID-19 vaccine

As part of winter preparedness, ATAGI have provided recommendations for an additional COVID-19 vaccine winter booster dose for select groups who have been identified as being at highest risk of severe COVID-19 disease. These groups include: 

  • individuals aged ≥ 65 years   
  • residents of aged care or disability care facilities  
  • individuals aged ≥ 16 years with severe immunocompromise 
  • Aboriginal and Torres Strait Islander people aged ≥ 50 years. 

The rollout of winter booster doses will commence from April in line with the 2022 influenza vaccination program, with both vaccines able to be co-administered where appropriate. Winter booster doses of COVID-19 vaccines can be administered from ≥ 4 months since the previous booster dose/confirmed SARS-CoV-2 infection (whichever is later).

mRNA vaccines (Comirnaty (Pfizer) or Spikevax (Moderna)) remain the recommended brands for use as booster doses, with Vaxzevria (AstraZeneca) available for those who have a contraindication to mRNA vaccines. Nuvaxovid (Novavax) may be used in circumstances where no other vaccine brand is deemed suitable.

ATAGI suggests that there is currently insufficient evidence at this time to support a recommendation for additional boosters for other individuals. For these groups, protection from a primary course of COVID-19 vaccine followed by 1 booster dose continues to provide good protection against hospitalisation with COVID-19 disease. Further recommendations may be considered in the future as more evidence emerges.

To read the advice in full please follow the link below.  

ATAGI statement on recommendations on a winter booster dose of COVID-19 vaccine


The Conversation: Do COVID boosters cause more or fewer side effects? How quickly does protection wane? Your questions answered

With more than 2,400 people currently in hospital, the Australian Technical Advisory Group on Immunisation (ATAGI) recommends Australians aged 16 years and older have a COVID-19 booster vaccine to ensure high levels of protection against severe disease and hospitalisation. A booster dose of the COVID vaccine, three months following the completion of the primary course can provide a similar level of protection against Omicron as two primary doses against Delta. 

Additionally, data shows that the booster dose renders milder side effects compared to the first 2 doses with less than 1% of people reporting the need for a medical consultation. 

This article explores the benefits of a booster vaccine compared to the primary 2 doses, the time frame recommendation for receiving a booster following COVID infection, and whether additional vaccine doses will be required in the future.  

Follow the link below to read the full article:

Do COVID boosters cause more or fewer side effects? How quickly does protection wane? Your questions answered 


Sydney Morning Herald: Fourth COVID vaccine shot found to be highly effective

A preliminary study published by Israel’s Sheba medical centre found that a fourth dose of the COVID-19 vaccine administered to people 60 years and over, made them three times more resistant to serious illness and twice as resistant to infection than thrice-vaccinated people in the same age group.  

Moving forward, Pfizer’s chief executive Albert Bourla said annual COVID-19 vaccine boosters would be preferable to more frequent boosters

At this stage, Pfizer is nearly ready to file for approval for a redesigned vaccine that targets Omicron while still protecting against other variants.  

To read the full article, follow the link below: 

Fourth COVID vaccine shot found to be highly effective 


ABC: Should I mix or match my booster? Your COVID-19 vaccine questions answered

ATAGI recommends that everyone aged 18 years and over to receive a booster dose of the Pfizer or Moderna COVID-19 vaccine, regardless of which vaccine they received for their primary course.

With over 5 million people now triple jabbed, Australia’s COVID-19 booster rollout is well underway.

This article explores some of the clinical data and considerations regarding the COVID-19 boosters.

To read the full article, follow the link below.
Should I mix or match my booster? Your COVID-19 vaccine questions answered